Novo Nordisk A/S’s (NVO) “Sell” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their sell rating on shares of Novo Nordisk A/S (NYSE:NVO) in a research report released on Tuesday morning.

A number of other research analysts also recently issued reports on NVO. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Thursday, September 10th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Berenberg Bank set a $47.00 price objective on shares of Novo Nordisk A/S and gave the company a “hold” rating in a research report on Wednesday, August 12th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Tuesday. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Four investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $60.14.

Novo Nordisk A/S Stock Up 0.6%

NVO stock traded up $0.23 during mid-day trading on Tuesday, reaching $38.54. The company had a trading volume of 11,953,804 shares, compared to its average volume of 17,066,984. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The firm has a fifty day simple moving average of $45.28 and a 200 day simple moving average of $43.86. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.66 and a current ratio of 0.87. The company has a market capitalization of $172.09 billion, a price-to-earnings ratio of 9.42, a price-to-earnings-growth ratio of 1.27 and a beta of 0.74.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The company had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Analysts forecast that Novo Nordisk A/S will post 3.54 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were paid a dividend of $0.5786 per share. This is a drop from Novo Nordisk A/S’s previous dividend of $1.2751. This represents a yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 19.80%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently made changes to their positions in NVO. QRG Capital Management Inc. raised its position in shares of Novo Nordisk A/S by 23.0% during the second quarter. QRG Capital Management Inc. now owns 175,187 shares of the company’s stock worth $8,398,000 after acquiring an additional 32,756 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Novo Nordisk A/S by 9.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 16,205 shares of the company’s stock valued at $777,000 after buying an additional 1,444 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in Novo Nordisk A/S by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after buying an additional 71,684 shares in the last quarter. State Street Corp grew its stake in shares of Novo Nordisk A/S by 0.6% in the second quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares in the last quarter. Finally, Wellington Altus USA Inc. acquired a new position in Novo Nordisk A/S during the second quarter worth approximately $115,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo signed an exclusive licensing agreement with Hengrui Pharma for HRS-1596, a phase 1-ready, once-weekly oral GLP-1/GIP drug candidate. The deal is worth up to $2.6 billion, including $300 million upfront, and expands Novo’s pipeline of oral obesity treatments and potential alternatives to daily pills. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: A real-world analysis presented at a medical meeting found that patients switching from Wegovy or Eli Lilly’s Zepbound injections to Novo’s daily Wegovy pill lost about 4% of their body weight over three months. The data supports demand for a more convenient oral option and helps Novo defend its position in the obesity market. People switching to Novo’s Wegovy pill from obesity injections kept losing weight in real-world study
• Positive Sentiment: Novo reported real-world evidence suggesting patients who increased Ozempic to 2 mg had a 6% lower risk of major cardiovascular events than patients who switched to Lilly’s Mounjaro. While observational rather than a head-to-head clinical trial, the finding strengthens Ozempic’s differentiation. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Recent CagriSema phase 3 data showed 12.4% weight loss after 60 weeks in a type 2 diabetes study, improving confidence in another late-stage obesity asset. Novo is also pursuing longer-acting delivery technology through its Nanexa collaboration. Novo Nordisk Just Beat Lilly in a Trial
• Neutral Sentiment: Novo’s share-repurchase program remains in progress, with a broader authorization of up to DKK 15 billion over 12 months. Buybacks may provide technical support, but they do not resolve the company’s growth and competitive challenges. Novo Nordisk share repurchase programme
• Negative Sentiment: Investors remain concerned about an “uninspiring” growth outlook and competition from Lilly. Lilly has claimed its oral obesity treatment, Foundayo, delivers greater weight loss and better blood-sugar control than higher-dose Ozempic, while some analysts continue to rate NVO only “Hold.” Novo Nordisk Gives Uninspiring Outlook

About Novo Nordisk A/S

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.